Regulatory  	Regulatory  	 JJ	B-NP
challenges  	challenges  	 NNS	I-NP
associated  	associated  	 VBN	O
with  	with  	 IN	O
conducting  	conducting  	 VBG	O
multicountry  	multicountry  	 JJ	B-NP
clinical  	clinical  	 JJ	I-NP
trials  	trials  	 NNS	I-NP
in  	in  	 IN	O
resource-limited  	resource-limited  	 JJ	B-NP
settings  	settings  	 NNS	I-NP
International  	International  	 JJ	O
public  	public  	 JJ	B-NP
health  	health  	 NN	I-NP
and  	and  	 CC	O
infectious  	infectious  	 JJ	B-NP
diseases  	diseases  	 NNS	I-NP
research  	research  	 NN	I-NP
has  	has  	 VBZ	O
expanded  	expanded  	 VBN	O
to  	to  	 TO	O
become  	become  	 VB	O
a  	a  	 DT	O
global  	global  	 JJ	O
enterprise  	enterprise  	 NN	O
transcending  	transcending  	 VBZ	O
national  	national  	 JJ	O
and  	and  	 CC	O
continental  	continental  	 JJ	O
borders  	borders  	 NNS	O
in  	in  	 IN	O
organized  	organized  	 JJ	O
networks  	networks  	 NNS	O
addressing  	addressing  	 VBG	B-NP
high-impact  	high-impact  	 JJ	I-NP
diseases 	diseases 	 NNS	I-NP
.  	.  	 .	O
In  	In  	 IN	O
conducting  	conducting  	 VBG	O
multicountry  	multicountry  	 JJ	B-NP
clinical  	clinical  	 JJ	I-NP
trials 	trials 	 NNS	I-NP
,  	,  	 ,	O
sponsors  	sponsors  	 NNS	O
and  	and  	 CC	O
investigators  	investigators  	 NNS	B-NP
have  	have  	 VBP	O
to  	to  	 TO	O
ensure  	ensure  	 VB	O
that  	that  	 IN	O
they  	they  	 PRP	O
meet  	meet  	 VBP	O
regulatory  	regulatory  	 JJ	B-NP
requirements  	requirements  	 NNS	I-NP
in  	in  	 IN	O
all  	all  	 DT	O
countries  	countries  	 NNS	O
in  	in  	 IN	O
which  	which  	 WDT	O
the  	the  	 DT	O
clinical  	clinical  	 JJ	B-NP
trials  	trials  	 NNS	I-NP
will  	will  	 MD	O
be  	be  	 VB	O
conducted 	conducted 	 VBN	O
.  	.  	 .	O
Some  	Some  	 DT	O
of  	of  	 IN	O
these  	these  	 DT	O
requirements  	requirements  	 NNS	B-NP
include  	include  	 VBP	O
review  	review  	 NN	O
and  	and  	 CC	O
approval  	approval  	 NN	O
by  	by  	 IN	O
national  	national  	 JJ	O
drug  	drug  	 NN	O
regulatory  	regulatory  	 JJ	B-NP
authorities  	authorities  	 NNS	I-NP
and  	and  	 CC	O
recognized  	recognized  	 VBN	B-NP
research  	research  	 NN	I-NP
ethics  	ethics  	 NNS	I-NP
committees 	committees 	 NNS	I-NP
.  	.  	 .	O
A  	A  	 DT	O
limiting  	limiting  	 JJ	O
factor  	factor  	 NN	B-NP
to  	to  	 TO	O
the  	the  	 DT	O
efficient  	efficient  	 JJ	O
conduct  	conduct  	 NN	O
of  	of  	 IN	O
multicountry  	multicountry  	 JJ	B-NP
clinical  	clinical  	 JJ	I-NP
trials  	trials  	 NNS	I-NP
is  	is  	 VBZ	O
the  	the  	 DT	O
regulatory  	regulatory  	 JJ	B-NP
environment  	environment  	 NN	I-NP
in  	in  	 IN	O
each  	each  	 DT	O
collaborating  	collaborating  	 JJ	O
country 	country 	 NN	O
,  	,  	 ,	O
with  	with  	 IN	O
significant  	significant  	 JJ	O
differences  	differences  	 NNS	O
determined  	determined  	 VBN	O
by  	by  	 IN	O
various  	various  	 JJ	O
factors  	factors  	 NNS	O
including  	including  	 VBG	O
the  	the  	 DT	O
laws  	laws  	 NNS	O
and  	and  	 CC	O
the  	the  	 DT	O
procedures  	procedures  	 NNS	O
used  	used  	 VBN	O
in  	in  	 IN	O
each  	each  	 DT	O
country 	country 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
long  	long  	 JJ	O
regulatory  	regulatory  	 JJ	B-NP
processes  	processes  	 NNS	I-NP
in  	in  	 IN	O
resource-limited  	resource-limited  	 JJ	B-NP
countries  	countries  	 NNS	I-NP
may  	may  	 MD	O
hinder  	hinder  	 VB	O
the  	the  	 DT	O
efficient  	efficient  	 JJ	O
implementation  	implementation  	 NN	B-NP
of  	of  	 IN	I-NP
multisite  	multisite  	 JJ	I-NP
clinical  	clinical  	 JJ	I-NP
trials 	trials 	 NNS	I-NP
,  	,  	 ,	O
delaying  	delaying  	 VBG	B-NP
research  	research  	 NN	I-NP
important  	important  	 JJ	O
to  	to  	 TO	O
the  	the  	 DT	O
health  	health  	 NN	O
of  	of  	 IN	O
populations  	populations  	 NNS	O
in  	in  	 IN	O
these  	these  	 DT	O
countries  	countries  	 NNS	O
and  	and  	 CC	O
costing  	costing  	 VBG	B-NP
millions  	millions  	 NNS	I-NP
of  	of  	 IN	O
dollars  	dollars  	 NNS	O
a  	a  	 DT	O
year 	year 	 NN	O
.  	.  	 .	O
